135 related articles for article (PubMed ID: 22487536)
1. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer.
Matulonis UA; Pereira L; Liu J; Lee H; Lee J; Whalen C; Campos S; Atkinson T; Hill M; Berlin S
Gynecol Oncol; 2012 Jul; 126(1):41-6. PubMed ID: 22487536
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Sánchez-Muñoz A; Mendiola C; Pérez-Ruiz E; Rodríguez-Sánchez CA; Jurado JM; Alonso-Carrión L; Ghanem I; de Velasco G; Quero-Blanco C; Alba E
Oncology; 2010; 79(1-2):98-104. PubMed ID: 21079407
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.
Chura JC; Van Iseghem K; Downs LS; Carson LF; Judson PL
Gynecol Oncol; 2007 Nov; 107(2):326-30. PubMed ID: 17706754
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
6. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer.
Hurt JD; Richardson DL; Seamon LG; Fowler JF; Copeland LJ; Cohn DE; Eisenhauer E; Salani R; O'Malley DM
Gynecol Oncol; 2009 Dec; 115(3):396-400. PubMed ID: 19804901
[TBL] [Abstract][Full Text] [Related]
7. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.
Kudoh K; Takano M; Kouta H; Kikuchi R; Kita T; Miyamoto M; Watanabe A; Kato M; Goto T; Kikuchi Y
Gynecol Oncol; 2011 Aug; 122(2):233-7. PubMed ID: 21601912
[TBL] [Abstract][Full Text] [Related]
8. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
Simpkins F; Belinson JL; Rose PG
Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
[TBL] [Abstract][Full Text] [Related]
9. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
[TBL] [Abstract][Full Text] [Related]
11. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
Jurado JM; Sánchez A; Pajares B; Pérez E; Alonso L; Alba E
Clin Transl Oncol; 2008 Sep; 10(9):583-6. PubMed ID: 18796376
[TBL] [Abstract][Full Text] [Related]
12. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
[TBL] [Abstract][Full Text] [Related]
13. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
[TBL] [Abstract][Full Text] [Related]
14. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study.
McGonigle KF; Muntz HG; Vuky J; Paley PJ; Veljovich DS; Greer BE; Goff BA; Gray HJ; Malpass TW
Cancer; 2011 Aug; 117(16):3731-40. PubMed ID: 21815133
[TBL] [Abstract][Full Text] [Related]
15. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer.
Monk BJ; Han E; Josephs-Cowan CA; Pugmire G; Burger RA
Gynecol Oncol; 2006 Aug; 102(2):140-4. PubMed ID: 16790264
[TBL] [Abstract][Full Text] [Related]
16. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?
Backes FJ; Richardson DL; McCann GA; Smith B; Salani R; Eisenhauer EL; Fowler JM; Copeland LJ; Cohn DE; O'Malley DM
Int J Gynecol Cancer; 2013 Jun; 23(5):833-8. PubMed ID: 23640292
[TBL] [Abstract][Full Text] [Related]
17. ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer.
Matulonis UA; Lee J; Lasonde B; Tew WP; Yehwalashet A; Matei D; Behbakht K; Grothusen J; Fleming G; Lee NK; Arnott J; Bray MR; Fletcher G; Brokx RD; Castonguay V; Mackay H; Sidor CF; Oza AM
Eur J Cancer; 2013 Jan; 49(1):121-31. PubMed ID: 22921155
[TBL] [Abstract][Full Text] [Related]
18. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
[TBL] [Abstract][Full Text] [Related]
19. Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer.
Hanjani P; Nolte S; Shahin MS
Gynecol Oncol; 2002 May; 85(2):278-84. PubMed ID: 11972388
[TBL] [Abstract][Full Text] [Related]
20. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.
Dellapasqua S; Bertolini F; Bagnardi V; Campagnoli E; Scarano E; Torrisi R; Shaked Y; Mancuso P; Goldhirsch A; Rocca A; Pietri E; Colleoni M
J Clin Oncol; 2008 Oct; 26(30):4899-905. PubMed ID: 18794539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]